[Dalbavancin and its use in the treatment of methicillin-resistant Staphylococcus aureus - induced upper limb phlegmon].
Klin Mikrobiol Infekc Lek. 2020 Jun;26(2):51-53
Authors: Zahornacký O, Novotný M
The article discusses dalbavancin, a relatively new lipoglycopeptide antibiotic brought to market. It briefly describes the spectrum and mechanism of its antibacterial effect and dosing regimens that can be used in the treatment of skin and soft tissue infections. The authors present a case of a patient with shoulder phlegmon caused by MRSA who was successfully treated with this antibiotic.
PMID: 33389741 [PubMed - as supplied by publisher]